PY2201430A - Compuestos y composiciones para tratar condiciones asociadas con la actividad de sting - Google Patents

Compuestos y composiciones para tratar condiciones asociadas con la actividad de sting

Info

Publication number
PY2201430A
PY2201430A PY202202201430A PY2201430A PY2201430A PY 2201430 A PY2201430 A PY 2201430A PY 202202201430 A PY202202201430 A PY 202202201430A PY 2201430 A PY2201430 A PY 2201430A PY 2201430 A PY2201430 A PY 2201430A
Authority
PY
Paraguay
Prior art keywords
sting
compositions
compounds
conditions associated
treating conditions
Prior art date
Application number
PY202202201430A
Other languages
English (en)
Inventor
Jason Katz
William R Roush
Hans Martin Seidel
Shankar Venkatraman
Original Assignee
Ifm Due Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ifm Due Inc filed Critical Ifm Due Inc
Publication of PY2201430A publication Critical patent/PY2201430A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción presenta entidades químicas (por ejemplo, un compuesto o una sal farmacéuticamente aceptable, y/o hidrato, y/o cocristal, y/o combinación de fármacos del compuesto) que inhiben (por ejemplo, antagonizan) el estimulador de genes de interferón (STING). Estas entidades químicas son útiles, por ejemplo, para tratar una condición, enfermedad o trastorno en el que el aumento (por ejemplo, exceso) de activación de STING (por ejemplo, señalización de STING) contribuye a la patología y/o síntomas y/o progresión de la condición, enfermedad o trastorno (por ejemplo, cáncer) en un sujeto (por ejemplo, un humano). La presente descripción también presenta composiciones que contienen los mismos, así como métodos para usarlos y fabricarlos.
PY202202201430A 2021-01-08 2022-01-10 Compuestos y composiciones para tratar condiciones asociadas con la actividad de sting PY2201430A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163135336P 2021-01-08 2021-01-08

Publications (1)

Publication Number Publication Date
PY2201430A true PY2201430A (es) 2022-08-12

Family

ID=80122916

Family Applications (1)

Application Number Title Priority Date Filing Date
PY202202201430A PY2201430A (es) 2021-01-08 2022-01-10 Compuestos y composiciones para tratar condiciones asociadas con la actividad de sting

Country Status (9)

Country Link
US (1) US12152018B2 (es)
EP (1) EP4274824A1 (es)
JP (1) JP2024502474A (es)
CN (1) CN117529475A (es)
AR (1) AR124598A1 (es)
PY (1) PY2201430A (es)
TW (1) TW202235073A (es)
UY (1) UY39608A (es)
WO (1) WO2022150585A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021067801A1 (en) * 2019-10-03 2021-04-08 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022150585A1 (en) 2021-01-08 2022-07-14 Ifm Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
WO2022150543A1 (en) * 2021-01-08 2022-07-14 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
PY2269135A (es) 2021-08-10 2024-01-29 Ifm Due Inc Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
CN116789641A (zh) * 2022-03-17 2023-09-22 中国科学院上海药物研究所 二氢异喹啉类化合物及其医药用途
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2025079045A1 (en) * 2023-10-12 2025-04-17 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
CN119285617B (zh) * 2024-09-27 2025-11-18 沈阳药科大学 1,3,5-三取代吲哚衍生物及其应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439906A (en) 1993-11-22 1995-08-08 Merck & Co., Inc. Antiarrhythmic benzodiazepines
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
US6699879B1 (en) 1999-02-12 2004-03-02 Smithkline Beecham P.L.C. Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
EP1347972A1 (en) 2000-12-19 2003-10-01 Smithkline Beecham Plc Pyrazolo 3,4-c]pyridines as gsk-3 inhibitors
DE60208630T2 (de) 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
CZ2004359A3 (cs) 2001-09-26 2004-09-15 Pharmacia Italia S.P.A. Aminoindazolové deriváty aktivní jako inhibitory kinázy, způsob jejich přípravy a farmaceutické prostředky obsahující tyto deriváty
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
JP2003192587A (ja) 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
AU2003245700A1 (en) 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
JP4751063B2 (ja) 2002-05-17 2011-08-17 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害剤として活性のアミノインダゾール誘導体、それらの調製方法、及びそれらを含む薬学的組成物
KR101166745B1 (ko) 2002-09-05 2012-07-23 아방티 파르마 소시에테 아노님 의약으로서의 신규한 아미노인다졸 유도체 및 이를 함유하는 약제학적 조성물
PL376789A1 (pl) 2002-12-12 2006-01-09 Aventis Pharma S.A. Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
CA2553433A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
WO2007024944A1 (en) 2005-08-25 2007-03-01 Schering Corporation Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
DE102006005180A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
EP2137187A1 (en) 2007-03-28 2009-12-30 Inovacia AB Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase
BRPI0811065A2 (pt) * 2007-06-08 2014-12-02 Abbott Lab Indazóis 5-heteroaril substituídos como inibidores de quinase
EP2157859A4 (en) * 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
EP2226315A4 (en) 2007-12-28 2012-01-25 Carna Biosciences Inc 2-aminoquinazoline DERIVATIVE
EP2254598B1 (en) 2008-02-13 2013-07-10 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
JP2009286773A (ja) * 2008-03-14 2009-12-10 Bayer Cropscience Ag 殺虫性縮環式アリール類
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9701631B2 (en) 2010-12-03 2017-07-11 The Trustees Of The University Of Pennsylvania TIP60 inhibitors
KR20120063283A (ko) 2010-12-07 2012-06-15 제일약품주식회사 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
CA2830780A1 (en) 2011-03-22 2012-09-27 Amgen Inc. Azole compounds as pim inhibitors
KR102001364B1 (ko) 2011-05-13 2019-07-22 어레이 바이오파마 인크. Trka 키나제 저해제로서의 피롤리디닐 유레아 및 피롤리디닐 티오유레아 화합물
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
ME03586B (me) 2013-05-18 2020-07-20 Univ California Sastavi i metode za aktiviranje signaliziranja koje je zavisno od .,stimulatora gena za interferon"
EP3060056A4 (en) 2013-10-21 2017-10-18 Drexel University Use of sting agonists to treat chronic hepatitis b virus infection
CA2936551A1 (en) 2014-01-24 2015-07-30 Confluence Life Sciences, Inc. Substituted pyrrolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases
US20170273922A1 (en) 2014-10-03 2017-09-28 The Royal Institution For The Advacement Of Learning/Mcgill University Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
NZ739185A (en) 2015-07-30 2022-10-28 Calgent Biotechnology Co Ltd Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3350188B1 (en) 2015-08-27 2024-03-13 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
US20170146519A1 (en) 2015-11-20 2017-05-25 Oregon Health & Science University Sting agonists and methods of selecting sting agonists
KR20180132783A (ko) 2016-04-07 2018-12-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조절제로서 유용한 헤테로사이클릭 아미드
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2018132372A1 (en) 2017-01-10 2018-07-19 Sanford Burnham Prebys Medical Discovery Institute Small molecule activators of nicotinamide phosphoribosyltransferase (nampt) and uses thereof
CA3067257A1 (en) 2017-06-22 2018-12-27 Curadev Pharma Limited Small molecule modulators of human sting
JP2020524718A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの複素環式小分子調節因子
FR3068914B1 (fr) 2017-07-11 2020-09-04 Michelin & Cie Procede de fabrication d'un bandage pneumatique avec une bande de roulement perfectionnee
CN109180649B (zh) 2017-08-18 2021-03-12 四川百利药业有限责任公司 一种含吲哚环的ido抑制剂及其制备方法
WO2019122202A1 (en) 2017-12-20 2019-06-27 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors
CA3095233A1 (en) 2018-03-28 2019-10-03 Bayer Pharma Aktiengesellschaft 4-(3-amino-6-fluoro-1h-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dic arbonitrile compounds for treating hyperproliferative disorders
EP3556362A1 (en) 2018-04-16 2019-10-23 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors
WO2020010155A1 (en) * 2018-07-03 2020-01-09 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
MA53095A (fr) 2018-07-03 2021-05-12 Ifm Due Inc Composés et compositions pour traiter des états pathologiques associés à une activité de sting
MA55138A (fr) 2018-11-19 2021-09-29 Ifm Due Inc Composés et compositions pour traiter des états pathologiques associés à une activité de sting
WO2020106741A1 (en) 2018-11-19 2020-05-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2020150439A1 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2020150417A2 (en) * 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN109734677A (zh) 2019-03-07 2019-05-10 四川大学 抑制组蛋白赖氨酸甲基转移酶nsd2的小分子化合物及其应用
US20220160705A1 (en) 2019-03-20 2022-05-26 Cornell University Methods for controlling prostaglandin-mediated biological processes
WO2020236586A1 (en) 2019-05-17 2020-11-26 Ifm Due, Inc. N-hetaryl-squaramide compounds for treating conditions associated with sting activity
US20220227760A1 (en) 2019-05-29 2022-07-21 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
EP3983383A1 (en) 2019-06-14 2022-04-20 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
EP3987291A1 (en) 2019-06-21 2022-04-27 IFM Due, Inc. Methods of treating cancer
WO2021067791A1 (en) 2019-10-03 2021-04-08 Ifm Due, Inc. Oxalamide compounds and compositions for treating conditions associated with sting activity
PY2060666A (es) 2019-10-03 2021-09-24 Ifm Due Inc Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
WO2021067801A1 (en) 2019-10-03 2021-04-08 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2021138419A1 (en) 2019-12-31 2021-07-08 Ifm Due, Inc, Compounds and compositions for treating conditions associated with sting activity
UY39006A (es) 2019-12-31 2021-07-30 Ifm Due Inc Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
US20230250106A1 (en) 2020-07-15 2023-08-10 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022015938A1 (en) 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US20220024906A1 (en) 2020-07-15 2022-01-27 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
EP4182310A1 (en) 2020-07-15 2023-05-24 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US20230365553A1 (en) 2020-07-15 2023-11-16 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
TW202216685A (zh) 2020-07-15 2022-05-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
US20220024919A1 (en) 2020-07-15 2022-01-27 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022133098A2 (en) 2020-12-16 2022-06-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
EP4263523A2 (en) 2020-12-16 2023-10-25 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022140387A1 (en) 2020-12-22 2022-06-30 Ifm Due, Inc. Methods of treating cancer
US20240060982A1 (en) 2020-12-22 2024-02-22 Ifm Due, Inc. Methods of treating cancer
WO2022140410A1 (en) 2020-12-22 2022-06-30 Ifm Due, Inc. Methods of treating cancer
EP4267126A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
CN116964045A (zh) 2021-01-08 2023-10-27 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的草酰胺化合物和组合物
WO2022150585A1 (en) 2021-01-08 2022-07-14 Ifm Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
WO2022150543A1 (en) 2021-01-08 2022-07-14 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN117480169A (zh) 2021-01-08 2024-01-30 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
PY2269135A (es) 2021-08-10 2024-01-29 Ifm Due Inc Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
EP4463441A1 (en) 2022-01-12 2024-11-20 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2023137034A1 (en) 2022-01-12 2023-07-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Also Published As

Publication number Publication date
US20220242852A1 (en) 2022-08-04
JP2024502474A (ja) 2024-01-19
TW202235073A (zh) 2022-09-16
WO2022150585A1 (en) 2022-07-14
AR124598A1 (es) 2023-04-12
EP4274824A1 (en) 2023-11-15
US12152018B2 (en) 2024-11-26
CN117529475A (zh) 2024-02-06
UY39608A (es) 2022-07-29

Similar Documents

Publication Publication Date Title
PY2089151A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
PY2026348A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
PY2157405A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting
PY2089159A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
PY2060666A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
UY39608A (es) Compuestos y composiciones para tratar condiciones asociadas con la actividad de sting
CO2019008932A2 (es) Imidazo-quinolinas sustituidas como moduladores de nlrp3
EA201891565A1 (ru) Соединения и композиции для лечения состояний, ассоциированных с активностью sting
PY2301792A (es) Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting
MX2018012249A (es) Moduladores de nlpr3.
CO2024002311A2 (es) Compuestos y composiciones para tratar condiciones asociadas con actividad de sting
WO2022133046A3 (en) Compounds and compositions for treating conditions associated with sting activity
ECSP20067394A (es) Inhibidores de cinasa dependientes de ciclina
MX2022000271A (es) Inhibidores de la quinasa progenitora hematopoyetica 1 y usos de los mismos.
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
MX2025012450A (es) Inhibidores de prmt5 y usos de estos
MX2020003868A (es) Compuesto heterociclico como inhibidor de proteina quinasa.
CL2025004052A1 (es) Derivados pirazolo[3,2-c]piridinona, inhibidores egfr y/o her2; composición; uso en cáncer
WO2022133098A3 (en) Compounds and compositions for treating conditions associated with sting activity
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
CL2021001389A1 (es) Formulaciones en cápsula
MX2021003904A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
MX2024005237A (es) Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo.
ECSP066457A (es) 5-arilpirimidinas como agentes anti-cancer
CL2024000114A1 (es) Compuestos terapéuticos y procedimientos.